120 related articles for article (PubMed ID: 36733110)
1. [Two Cases of Recurrent Colon Cancer with BRAF Mutation].
Fujie Y; Nishimura H; Sata A; Adachi S; Higaki N; Ueshima S; Hayashida H; Ohnishi T
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1485-1487. PubMed ID: 36733110
[TBL] [Abstract][Full Text] [Related]
2. Encorafenib, Binimetinib, and Cetuximab in
Kopetz S; Grothey A; Yaeger R; Van Cutsem E; Desai J; Yoshino T; Wasan H; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Pfeiffer P; Orlov S; Lonardi S; Elez E; Kim TW; Schellens JHM; Guo C; Krishnan A; Dekervel J; Morris V; Calvo Ferrandiz A; Tarpgaard LS; Braun M; Gollerkeri A; Keir C; Maharry K; Pickard M; Christy-Bittel J; Anderson L; Sandor V; Tabernero J
N Engl J Med; 2019 Oct; 381(17):1632-1643. PubMed ID: 31566309
[TBL] [Abstract][Full Text] [Related]
3. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated
Tabernero J; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Elez E; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
J Clin Oncol; 2021 Feb; 39(4):273-284. PubMed ID: 33503393
[TBL] [Abstract][Full Text] [Related]
4. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
[TBL] [Abstract][Full Text] [Related]
5. Encorafenib, binimetinib and cetuximab combined therapy for patients with
Huijberts SC; van Geel RM; Bernards R; Beijnen JH; Steeghs N
Future Oncol; 2020 Feb; 16(6):161-173. PubMed ID: 32027186
[TBL] [Abstract][Full Text] [Related]
6. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
7. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer].
Kono T; Miyata R; Yoshimatsu K; Koike T; Shiozawa S; Hanada M; Ajihara T; Naritomi T; Fukuya Y
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1154-1156. PubMed ID: 36281617
[TBL] [Abstract][Full Text] [Related]
9. [A Case of BRAF V600E-Mutant Colorectal Cancer Treated Effectively by Encorafenib, Binimetinib, and Cetuximab Triple Therapy].
Sakamoto S; Tagai N; Shimada M; Kurebayashi H; Sawai K; Morikawa M; Koneri K; Tamaki M; Murakami M; Hirono Y; Goi T
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1145-1147. PubMed ID: 36281614
[TBL] [Abstract][Full Text] [Related]
10. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
Al-Marrawi MY; Saroya BS; Brennan MC; Yang Z; Dykes TM; El-Deiry WS
Cancer Biol Ther; 2013 Aug; 14(8):703-10. PubMed ID: 23792568
[TBL] [Abstract][Full Text] [Related]
11. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.
Morris V; Overman MJ; Jiang ZQ; Garrett C; Agarwal S; Eng C; Kee B; Fogelman D; Dasari A; Wolff R; Maru D; Kopetz S
Clin Colorectal Cancer; 2014 Sep; 13(3):164-71. PubMed ID: 25069797
[TBL] [Abstract][Full Text] [Related]
12. Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAF
Ji J; Wang C; Fakih M
Clin Colorectal Cancer; 2022 Sep; 21(3):267-271. PubMed ID: 35039233
[No Abstract] [Full Text] [Related]
13. Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer.
Chouhan H; Sammour T; L Thomas M; W Moore J
Asia Pac J Clin Oncol; 2019 Feb; 15(1):69-74. PubMed ID: 30421554
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
15. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study.
Sakata H; Murase M; Kato T; Yamaguchi K; Sugihara K; Suzuki S; Yoshino T
Int J Clin Oncol; 2023 Jan; 28(1):139-144. PubMed ID: 36355316
[TBL] [Abstract][Full Text] [Related]
16. Current perspectives on the treatment of BRAF mutated colorectal carcinoma.
Batko S
Klin Onkol; 2020; 33(5):328-338. PubMed ID: 33108877
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer.
Lim B; Scicchitano A; Beachler C; Gusani N; Sarwani N; Yang Z; Staveley-O'Carroll K; Ashkenazi A; Portera C; El-Deiry WS
Cancer Biol Ther; 2013 Aug; 14(8):711-9. PubMed ID: 23792567
[TBL] [Abstract][Full Text] [Related]
18. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
Hong DS; Morris VK; El Osta B; Sorokin AV; Janku F; Fu S; Overman MJ; Piha-Paul S; Subbiah V; Kee B; Tsimberidou AM; Fogelman D; Bellido J; Shureiqi I; Huang H; Atkins J; Tarcic G; Sommer N; Lanman R; Meric-Bernstam F; Kopetz S
Cancer Discov; 2016 Dec; 6(12):1352-1365. PubMed ID: 27729313
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
Taieb J; Balogoun R; Le Malicot K; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Emile JF; Mulot C; Fratté S; Levaché CB; Saban-Roche L; Thaler J; Petersen LN; Bridgewater J; Perkins G; Lepage C; Van Cutsem E; Zaanan A; Laurent-Puig P;
Ann Oncol; 2017 Apr; 28(4):824-830. PubMed ID: 28031175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
